<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359345</url>
  </required_header>
  <id_info>
    <org_study_id>GADOLLINUM</org_study_id>
    <secondary_id>6553-30-04-86</secondary_id>
    <nct_id>NCT01359345</nct_id>
  </id_info>
  <brief_title>Nephrogenic Systemic Fibrosis With Gadollinum</brief_title>
  <acronym>NSF</acronym>
  <official_title>The Prevalence and Severity of Nephrogenic Systemic Fibrosis in Patients Whom Underwent Imaging With Gadollinium(MRI/MRA) in University Hospital of Tehran Heart Center in 2003-2008</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imam Khomeini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tehran Heart Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Imam Khomeini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently there is increasing reports of NEPHROGENIIC SYSTEMIC FIBROSIS(NSF) in patients with
      severe renal failure mainly in patients under dialysis in whom gadollinum is being used.

      The investigators will evaluate the prevalence and severity of NSF in patients with different
      degree of renal failure whom underwent imaging with Gadolinum.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NSF is a progressive and potentially fatal disease reported mainly in End Stage Renal Disease
      (ESRD) patients in whom Gadolinume been used as contrast agent. Skin is the main organ of
      involvement but other vital organs like myocard,lung,liver may also be involved.Gadollinum is
      known as a safe contrast in renal disease patients in comparison with conventional
      nephrotoxic radiocontrast agents,but with increasing reports of NSF with Gadollinum the use
      of this agent in renal failure patients is under question.

      We will retrospectively evaluate the occurrence of this complication in all patients with
      different degree of renal failure whom underwent MRA or MRI with Gadollinum in Tehran Heart
      Center since 2003 till now and we will describe the severity and distribution pattern of
      lesions and the relation of this complication to the severity of renal failure.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>occurrence of fibrosis</measure>
    <time_frame>after 2 month of exposure with gadollinum</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Nephrogenic Systemic Fibrosis</condition>
  <condition>Renal Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with renal failure in whom Gadollinume has being used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gadollinum</intervention_name>
    <description>use of on injection gadollinum Iv for imaging</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal Failure

          -  Use of Gadollinum

        Exclusion Criteria:

          -  No consent

          -  Age under 18
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad R Khatami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>TUMS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tehran Heart Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imam Khomeini Hospital</investigator_affiliation>
    <investigator_full_name>Mohammad Reza Khatami</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>NSF</keyword>
  <keyword>ESRD</keyword>
  <keyword>MRA</keyword>
  <keyword>MRI</keyword>
  <keyword>occurrence of NSF</keyword>
  <keyword>Use of Gadollinum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Nephrogenic Fibrosing Dermopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

